Pediatrix Medical Group, Inc.

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

MD$31.29-1.7%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024 (Unaudited)

Consolidated Balance Sheets

(in thousands, except share data)

	March 31, 2025	December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$98,978	$229,940
Short-term investments	120,198	118,566
Accounts receivable, net	242,529	259,990
Prepaid expenses	12,085	13,410
Income taxes receivable	10,272	12,614
Other current assets	7,608	5,087
Total current assets	491,670	639,607
Property and equipment, net	38,222	39,172
Goodwill	1,242,606	1,242,606
Intangible assets, net	10,387	11,595
Operating and finance lease right-of-use assets	39,866	39,267
Deferred income tax assets	99,379	103,855
Other assets	71,349	76,598
Total assets	$1,993,479	$2,152,700
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$234,173	$398,690
Current portion of debt and finance lease liabilities, net	22,128	20,545
Current portion of operating lease liabilities	12,174	12,704
Income taxes payable	2,577	2,171
Total current liabilities	271,052	434,110
Long-term debt and finance lease liabilities, net	590,476	597,119
Long-term operating lease liabilities	30,538	31,945
Long-term professional liabilities	246,942	257,455
Deferred income tax liabilities	34,424	34,246
Other liabilities	30,859	32,887
Total liabilities	1,204,291	1,387,762
Commitments and contingencies
Shareholders’ equity:
Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued	—	—
Common stock; $.01 par value; 200,000,000 shares authorized; 85,810,408 and 85,866,000 shares issued and outstanding, respectively	858	859
Additional paid-in capital	1,016,425	1,013,690
Accumulated other comprehensive loss	(292)	(1,071)
Retained deficit	(227,803)	(248,540)
Total shareholders’ equity	789,188	764,938
Total liabilities and shareholders’ equity	$1,993,479	$2,152,700

Consolidated Statements of Income and Comprehensive Income

(in thousands, except per share data)

	Three Months EndedMarch 31,
	2025	2024
Net revenue	$458,359	$495,101
Operating expenses:
Practice salaries and benefits	337,031	369,138
Practice supplies and other operating expenses	18,686	31,085
General and administrative expenses	58,604	60,198
Depreciation and amortization	5,332	10,308
Transformational and restructuring related expenses	6,605	8,480
Total operating expenses	426,258	479,209
Income from operations	32,101	15,892
Investment and other income	4,737	2,013
Interest expense	(9,154)	(10,599)
Equity in earnings of unconsolidated affiliate	406	518
Total non-operating expenses	(4,011)	(8,068)
Income before income taxes	28,090	7,824
Income tax provision	(7,353)	(3,789)
Net income	$20,737	$4,035
Other comprehensive income, net of tax
Unrealized holding gain on investments, net of tax of $255 and $20	779	60
Total comprehensive income	$21,516	$4,095
Per common and common equivalent share data:
Net income:
Basic	$0.25	$0.05
Diluted	$0.24	$0.05
Weighted average common shares:
Basic	84,435	82,863
Diluted	85,430	83,275

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.